GSK scored an early FDA win for zidesamtinib, now branded Jideytro, following its $10.6 billion acquisition of Nuvalent. The U.S. approval covers adults with locally advanced or metastatic ROS1-positive non-small-cell lung cancer who previously received a ROS1 kinase inhibitor, setting up faster commercial ramp than a Sept. 18 review deadline implied.